Main menu

SeqOne Genomics and the French CNR-MAT pioneer the use of Oxford Nanopore sequencing technology to improve outcomes in kidney disease while reducing turnaround times

Get startedSubscribe
Return to News

SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies(CNR-MAT), aimed at improving outcomes in thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS), using Oxford Nanopore sequencing technology.

You can read the full announcement from SeqOne here.

  • Published on: February 9 2023

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust

© 2008 - 2025 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor, MinION, MinIT, MinKNOW, Plongle, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

ONT plc is a member of the producer compliance scheme run by ERP UK Ltd, who manage the submission of documentation in support of WEEE compliance for ONT plc’s manufacture and supply of Electrical and Electronic equipment in the UK.

ONT’s WEEE PRN is WEE/MM3828AA. See attached certificate for the submission period 2022.

English flag